Autoimmune conditions and NADPH oxidase defects

Details Autoimmune conditions and NADPH oxidase defects Autoimmune conditions and NADPH oxidase defects

2011-05-17

2011-05-17

Raghu, Ganapathirama (Department: 1652)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving oxidoreductase

C435S007800, C435S007400, C435S183000, C435S189000, C424S078020, C424S078080, C514S739000

Reexamination Certificate

active

07943338

ABSTRACT:
The invention relates to methods and materials involved in diagnosing and treating autoimmune conditions. In particular, the invention relates to methods and materials involved in diagnosing arthritis conditions that are accompanied by an NADPH oxidase deficiency, methods and materials involved in treating, preventing, or delaying the onset of arthritis conditions that are accompanied by an NADPH oxidase deficiency, and methods and materials involved in identifying agonists and antagonists of NADPH oxidase activity.

REFERENCES:
patent: 5128324 (1992-07-01), Walker et al.
patent: 5280048 (1994-01-01), Yamamoto et al.
patent: 5475029 (1995-12-01), Bradfute et al.
patent: 5763496 (1998-06-01), Holland
patent: 5902831 (1999-05-01), Holland et al.
patent: 2005/0232981 (2005-10-01), Ben-Sasson
patent: 1 964 422 (2000-06-01), None
patent: 2 285 047 (1995-06-01), None
patent: 61-257944 (1986-11-01), None
patent: 10-168090 (1998-06-01), None
patent: 2001-172171 (2001-06-01), None
patent: 1 827 623 (1993-07-01), None
patent: WO 90/14764 (1990-12-01), None
patent: WO 94/20080 (1994-09-01), None
patent: WO 98/01120 (1998-01-01), None
patent: WO 98/02182 (1998-01-01), None
patent: WO 99/12539 (1999-03-01), None
patent: WO 99/46367 (1999-09-01), None
patent: WO 00/40241 (2000-07-01), None
patent: WO 01/42435 (2001-06-01), None
patent: WO 01/42453 (2001-06-01), None
patent: WO 02/083058 (2002-10-01), None
patent: WO 02/083059 (2002-10-01), None
patent: WO 02/083122 (2002-10-01), None
patent: WO 03/095667 (2003-11-01), None
patent: WO 2005/105074 (2005-11-01), None
Åkerström, “Immunological Analysis of α1-Microglobulin in Different Mammalian and Chicken Serum,”J. Biol. Chem., 1985, 260:4839-4844.
Arakawa et al., “The effects of lidocaine on superoxide production and p47 Phox translocation in opsonized zymosan-activated neutrophils,”Anesth. Analg., 2001, 93(6):1501-1506.
Behi et al., “New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis,”Immunol. Lett., 2005, 96:11-26.
Biemond et al., “Superoxide production by polymorphonuclear leucocytes in rheumatoid arthritis and osteoarthritis: in vivo inhibition by the antirheumatic drug piroxicam due to interference with the activation of the NADPH-oxidase,”Ann. Rheum. Dis., 1986, 45(3):249-255.
Brown et al., “Mechanisms underlying mast cell influence on EAE disease course,”Mol. Immunol., 2001, 38:1373-1378.
Casimir et al., “Autosomal recessive chronic granulomatous disease caused by deletion at a dinucleotide repeat,”Proc. Natl. Acad. Sci. USA, 1991, 88:2753-2757.
Chihiro et al., “Novel thiazole derivatives as inhibitors of superoxide production by human neutrophils: synthesis and structure-activity relationship,”J. Med. Chem., 1995, 38(2):353-358.
Collins et al., “N-phenylamidines as selective inhibitors of human neuronal nitric oxide synthase: structure-activity studies and demonstration of in vivo activity,”J. Med. Chem., 1998, 41(15):2858-2871.
Crandall et al., “Bb2Bb3Regulation of Murine Lyme Arthritis Is Distinct fromNcf1and Independent of the Phagocyte Nicotinamide Adenine Dinucleotide Phosphate Oxidase,”Am. J. Pathol., 2005, 167(3):775-785.
Craner, “Sodium channels contribute to microglia/macrophage activation and function in EAE and MS,”GLIA, 2005, 49:220-229.
Cross and Jones, “The effect of the inhibitor diphenylene iodonium on the superoxide-generating system of neutrophils. Specific labeling of a component polypeptide of the oxidase,”Biochem. J., 1986, 237:111-116.
Dahlman et al., “Genome-Wide Linkage Analysis of Chronic Relapsing Experimental Automimmune Encephalomyelitis in the Rat Identifies a Major Susceptibility Locus on Chromosome 91,” J. Immunol., 1999, 162:2581-2588.
Dandona et al., “Acute suppressive effect of hydrocortisone on p47 subunit of nicotinamide adenine dinucleotide phosphate oxidase,”Metabolism, 2001, 50(5):548-552.
DeLeo et al., “NADPH oxidase activation and assembly during phagocytosis,”J. Immunol., 1999, 163:6732-6740.
De Mendez et al., “Specificity of p47phoxSH3 Domain Interactions in NADPH Oxidase Assembly and Activation,”Mol. Cell. Biol., 1997, 17(4):2177-2185.
Eggleton et al., “Differences in oxidative response of subpopulations of neutrophils from healthy subjects and patients with rheumatoid arthritis,”Ann. Rheum. Dis., 1995, 54:916-923.
El Bekay et al., “Activation of phagocytic cell NADPH oxidase by norfloxacin: a potential mechanism to explain its bactericidal action,”J. Leukoc. Biol., 2002, 71:255-261.
El Benna et al., “Phosphorylation of the Respiratory Burst Oxidase Subunit p47phoxas Determined by Two-dimensional Phosphopeptide Mapping,”J. Biol. Chem., 1996, 271:6374-6378.
El Benna et al., “NADPH Oxidase Priming and p47phoxPhosphorylation in Neutrophils from Synovial Fluid of Patients with Rheumatoid Arthritis and Spondylarthropathy,”Inflammation, 2002, 26(6):273-278.
Ellerman and Like, “A Major Histocompatibility Complex Class II Restriction for BioBreeding/Worcester Diabetes-inducing T Cells,”J. Exp. Med., 1995, 182:923-930.
Erickson et al., “Activation of Human Neutrophil NADPH Oxidase by Phosphatidic Acid or Diacylglycerol in a Cell-free System. Activity of diacylglycerol is dependent on its conversion to phosphatidic acid,”J. Biol. Chem., 1999, 274(32):22243-22250.
“Fatty alcohols,”Fatty Alcohols Aldehydes, 6 pages http://www.cyberlipid.org/simple/simp0003.htm, Nov. 11, 2003.
Faust et al., “The Phosphorylation Targets of p47phox, a Subunit of the Respiratory Burst Oxidase,”J. Clin. Invest., 1995, 96:1499-1505.
Gösele et al., “High-Throughput Scanning of the Rat Genome Using Interspersed Repetitive Sequence-PCR Markers,”Genomics, 2000, 69:287-294.
Griffiths et al., “Identification of Four New Quantitative Trait Loci Regulating Arthritis Severity and One New Quantitative Trait Locus Regulating Autoantibody Production in Rats with Collagen-Induced Arthritis,”Arthritis Rheum., 2000, 43:1278-1289.
Hancock and Jones, “The inhibition by diphenyleneiodonium and its analogues of superoxide generation by macrophages,”Biochem. J., 1987, 242:103-107.
Harbecke et al., “The synthetic non-toxic drug 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline inhibits neutrophil production of reactive oxygen species,”J. Leukoc. Biol., 1999, 65(6):771-777.
Holland et al., “Endothelial cell oxidant production: effect of NADPH oxidase inhibitors,”Endothelium, 2000, 7(2):109-119.
Hoogenraad et al., “The MurineCYLN2Gene: Genomic Organization, Chromosome Localization, and Comparison to the Human Gene That Is Located within the 7q11.23 Williams Syndrome Critical Region,”Genomics, 1998, 53:348-358.
Huang et al., “P47phox-deficient NADPH oxidase defect in neutrophils of diabetic mouse strains, C57BL/6J-m db/dbanddb/+,” J. Leukoc. Biol., 2000, 67:210-215.
Hultqvist and Holmdahl, “Ncf1(p47phox) polymorphism determines oxidative burst and the severity of arthritis in rats and mice,”Cell. Immunol., 2005, 233(2):97-101.
Hultqvist et al., “Enhanced autoimmunity, arthritis, and encephalomyelitis in mice with a reduced oxidative burst due to a mutation in theNcfl1gene,”Proc. Natl. Acad. Sci. USA, 2004, 101(34):12646-12651.
Human Genome Sequencing Center at Baylor College of Medicine at http://www.hgsc.bcm.tmc.edu/projects/rat, 3 pages Jan. 14, 2004.
Isoprene, Dictionary Search Results, On-line Medical Dictionary, printed Nov. 11, 2003, 1 page, http://cancerweb.ncl.ac.uk/cgi-bin/omd?isoprene.
Jackson et al., “The p47phoxMouse Knock-Out Model of Chronic Granulomatous Disease,”J. Exp. Med., 1995, 182:751-758.
Jackson et al., “T cells express a phagocyte-type NADPH oxidase that is activated af

Affiliated with

Also associated with

Rating

Autoimmune conditions and NADPH oxidase defects does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Autoimmune conditions and NADPH oxidase defects, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Autoimmune conditions and NADPH oxidase defects will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2645734